Current filters:


1 to 9 of 54 results

Pfizer says top-line Ph III results show safety of pain drug ALO-02 as expected


safety study of its investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride…

ALO-02naltrexoneNeurologicalOxycodone HClPfizerPharmaceuticalResearch

Alkermes completes Ph IIIb Vivitrol enrollment


US biotechnology firm Alkermes says that it has completed patient enrollment for the registration study…

Amino AcidsInjectionnaltrexoneNaltrexone XR InjPhysostigmine SalicylateReviaVivitrol

King's Embeda "effective for up to 12 months"


The USA's King Pharmaceuticals says that results from a Phase III study show that Embeda (morphine sulfate…

AvinzaEmbedaKing PharmaceuticalsMorphine SulfateMorphine Sulfate and Naltrexone HydrochloridenaltrexoneReviaRoxanol

FDA review of King's Embeda likely to extend into "early 2009"


King Pharmaceuticals says that the US Food and Drug Administration is continuing its review of the New…

EmbedaKing PharmaceuticalsMorphine Sulfate and Naltrexone HydrochloridenaltrexoneRevia

Alkermes regains the rights to Vivitrol from Cephalon along with $120M in revenue


Alkermes has regained the full US rights to alcoholism treatment Vivitrol (naltrexone) from fellow US…

CephalonnaltrexoneNaltrexone XR InjReviaVivitrol

1 to 9 of 54 results

Back to top